Portal:AOP/Mission

From WikiPathways

Revision as of 17:15, 6 January 2021

The purpose of this portal is to create a collection of AOPs on the molecular level and facilitating the use of high-throughput transcriptomic data in the AOP framework. The subjects of the first AOPs are linked to the use cases of the EU-ToxRisk program, based on [aopwiki.org AOP-Wiki] entries, and the CIAO project on COVID-19 AOPs.

List of molecular AOPs present in this portal (some are more defined than others):

• Mitochondrial Complex I inhibition leads to liver injury
• Mitochondrial Complex I inhibition leads to parkinsonian motor deficits
• Mitochondrial Complex I inhibition leads to Fanconi syndrome
• Protein alkylation leads to liver fibrosis
• Interaction with lung resident cell membrane components leads to lung fibrosis
• Multiple MIEs lead to liver steatosis
• ACE2 inhibition leads to increased mortality

Basic strategies and principles for general AOPs are described in this paper:

Villeneuve et al. (2014). Adverse Outcome Pathway (AOP) Development I: Strategies and Principles. Toxicological Sciences PubMed

The list of Featured Pathways is not static and can be updated at any time. If you know of a pathway that should be added, please contact Marvin Martens.